Erasmus MC spin-out developing next-generation TCR-T therapies for solid tumors.
| Date | Round | Amount |
|---|---|---|
| Dec 2025 | Funding round Rotterdam-based Pan Cancer T secured 10 million euros (5 in equity from Van Herk Ventures and others, 5 as a ministerial Innovation Credit) to bring its TCR-T therapy into the clinic against triple-negative breast cancer. | $11.6M |
| Jul 2024 | Seed Pan Cancer T, a Rotterdam T-cell-therapy biotech, closed a EUR4.25M seed extension with InnovationQuarter Capital. | $4.6M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.